GRI Bio, Inc. (GRI), a biotechnology company, Wednesday announced preclinical data showing that its lead drug candidate GRI-0621 has both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis.
The data were presented at the 2025 ATS International Conference.
GRI-0621 is currently being evaluated in a Phase 2a study in patients with Idiopathic Pulmonary Fibrosis (IPF). Topline results from the study are expected in the third quarter of 2025.
Results from 6-week interim analysis in ongoing Phase 2a study of GRI-0621 are anticipated in the second quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.